David Einhorn's ROIV Position Overview
David Einhorn (via Dme Capital Management, Lp) currently holds 2.15 M shares of Roivant Sciences Ltd. (ROIV) worth $59.63 M, representing 1.87% of the portfolio. First purchased in 2024-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, David Einhorn has maintained a strategic position in ROIV, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 620,470 shares. Largest reduction occurred in Q3 2025, reducing 2.28 M shares.
Analysis based on 13F filings available since 2013 Q2
David Einhorn's Roivant Sciences (ROIV) Holding Value Over Time
Track share changes against reported price movement
Quarterly Roivant Sciences (ROIV) Trades by David Einhorn
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +83,360 | Add 4.03% | 2.15 M | $27.70 |
| Q4 2025 | -206,220 | Reduce 9.06% | 2.07 M | $21.70 |
| Q3 2025 | -2.28 M | Reduce 50.00% | 2.28 M | $15.13 |
| Q2 2025 | -890,110 | Reduce 16.36% | 4.55 M | $11.27 |
| Q1 2025 | +170,100 | Add 3.23% | 5.44 M | $10.09 |
| Q4 2024 | -36,973 | Reduce 0.70% | 5.27 M | $11.83 |
| Q3 2024 | +497,080 | Add 10.33% | 5.31 M | $11.54 |
| Q2 2024 | +620,470 | Add 14.81% | 4.81 M | $10.57 |
| Q1 2024 | +4.19 M | Add 0.00% | 4.19 M | $10.54 |
David Einhorn's Roivant Sciences Investment FAQs
David Einhorn first purchased Roivant Sciences Ltd. (ROIV) in Q1 2024, acquiring 4,190,490 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn has held Roivant Sciences Ltd. (ROIV) for 9 quarters since Q1 2024.
David Einhorn's largest addition to Roivant Sciences Ltd. (ROIV) was in Q1 2024, adding 4,190,490 shares worth $44.17 M.
According to the latest 13F filing for Q1 2026, David Einhorn's firm, Dme Capital Management, Lp, owns 2,152,669 shares of Roivant Sciences Ltd. (ROIV), valued at approximately $59.63 M.
As of the Q1 2026 filing, Roivant Sciences Ltd. (ROIV) represents approximately 1.87% of David Einhorn's publicly disclosed stock portfolio, making it one of their key holdings.
David Einhorn's peak holding in Roivant Sciences Ltd. (ROIV) was 5,441,167 shares, as reported at the end of Q1 2025.